Aprepitant-d4 |
|
| Synonyms: 5-[[(2R,3S)-2-[(1R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl-d4)-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-triazol-3-one; Emend-d4; L 754030-d4; MK 0869-d4; MK 869-d4; ONO 7436-d4; | |
| Cat. No.: A66260 | CAS No.: 1133387-60-6 |
| MDL.: | Formula: C23H17D4F7N4O3 |
| F.W.538.45 | Purity: 99％ |
| Storage: No Data Available | |
| Size/Unit | Price | Qty | Availability | Price Total |
|---|---|---|---|---|
| 1mg | POA | Enter qty and click checkbox |
| Catalog Number： | A66260 | CAS No.: | 1133387-60-6 | |
| MDL: | Formula: | C23H17D4F7N4O3 | ||
| F.W.: | 538.45 | Purity: | 99％ | |
| Package: | Unit: | mg | ||
| Appearance: | No Data Available | M.P.: | No Data Available | |
| B.P.: | Density: | |||
| Optical Rotation: | Refractive Index: | |||
| Solubility: | Stability: | No Data Available | ||
| Storage: | No Data Available | Category: | Reference Standard | |
| Reference: | Hale, J.J., et al.: J. Med. Chem., 41, 4607 (1998); Campos, D., et al.: J. Clin. Oncol., 19, 1759 (2001); Van Belle, S., et al.: Cancer, 94, 3032 (2002); Majumdar, A.K., et al.: J. Clin. Pharmacol., 46, 291 (2006) | |||
| Application: | Aprepitant-d4 is a labeled analogue of Aprepitant, A novel selective neurokinin-1 (NK-1) receptor antagonist. In vitro studies using human liver microsomes indicate that Aprepitant is metabolised primarily by CYP3A4 with minor metabolism by CYP1A2 and CYP2C19, and no metabolism by CYP2D6, CYP2C9, or CYP2E1. Aprepitant-d4 is a potential treatment for chemotherapy induced nausea and vomiting. | |||
| Category: | Chiral Reagents, Heterocycles, Isotope Labelled Compounds, Pharmaceuticals, Intermediates & Fine Chemicals, | |||